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Recent progress in the treatment of pulmonary hypertension
as been remarkable over the past 2 decades. Three different path-
ays have been proposed to be involved in the pathogenesis of
ulmonary arterial hypertension (PAH) and targeted drugs modi-
ying each pathway have been developed. The diagnostic algorithm
s shown and a treatment algorithm, including these PAH-targeted
rugs, is recommended in the latest guidelines for the diagnosis
nd treatment of pulmonary hypertension [1]. More cases have
een diagnosed and treated with these drugs as a consequence of
ider recognition of pulmonary hypertension. However, the drugs
ave been proven to be effective only for treatment of PAH, which
s classiﬁed as Group 1 in the guidelines [1]. Therefore, the use of
AH-targeted drugs is not approved for other groups of pulmonary
ypertension because there is little evidence to prove that those
rugs are effective in diseases other than Group 1 PAH.
In this issue of Journal of Cardiology Cases, Naito et al. report
 case of pulmonary hypertension associated with intravascu-
ar lymphomatosis (IVL) [2]. The patient was 75 years old at
iagnosis and had a high pulmonary capillary wedge pressure.
hey ﬁrst diagnosed the patient with idiopathic PAH combined
ith pulmonary hypertension owing to left-sided heart disease
Group 2), and treated the patient with upfront combination ther-
py. After initiation of PAH-targeted therapies, the patient did
ot show improvement and 1 month later, IVL was diagnosed
ased on atypical cells detected in peripheral blood. After initia-
ion of chemotherapy to treat IVL, pulmonary hypertension was
lso improved.
IVL is a rare form of lymphoma which was described for the ﬁrst
ime in 1959 as angioendotheliomatosis [3]. IVL is characterized
y proliferation of malignant cells within the lumen of small blood
essels. The development of symptoms is assumed to be caused
y emboli or blood ﬂow disturbance due to obstruction of ves-
els by tumor cells. Although the central nervous system or skin
s frequently affected, the lung is also reported to be commonly
ffected. The lung is involved in approximately 60% of cases of IVL at
utopsy, irrespective of the presentation of respiratory symptoms
4]. The prognosis of patients who are diagnosed antemortem is
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ttp://dx.doi.org/10.1016/j.jccase.2013.03.015usually poor, with only 5 months median survival time [5]. Combi-
nation chemotherapy sometimes leads to complete remission and
long-term survival in cases of IVL [6].
Several cases of pulmonary hypertension caused by IVL have
been reported [7–9]. Although IVL was not pathologically con-
ﬁrmed in the present case described by Naito et al., pulmonary
hypertension might have been caused by invasion of IVL into the
pulmonary arteries. Chemotherapy might have been effective in
eliminating lymphoma cells in those pulmonary arteries and ulti-
mately could have led to amelioration of pulmonary hypertension.
In this case, pulmonary hypertension would be categorized as
Group 5 [1], which is not what the authors originally diagnosed,
PAH. Group 5 comprises a heterogeneous collection of diseases
with uncertain and multifactorial pathogenetic mechanisms lead-
ing to pulmonary hypertension, including hematological, systemic,
metabolic, and other rare disorders. Considering the common
involvement of the lungs by IVL and the fact that some patients
with IVL can be treated with combination chemotherapy, pul-
monary hypertension secondary to IVL may be reversible. IVL
should be considered in the differential diagnosis of pulmonary
hypertension.
The patient presented by Naito et al. was  elderly as a patient with
idiopathic PAH, which was  originally reported to occur predom-
inantly in younger women  [10]. Of course, age at diagnosis is not
the only factor for ruling out the diagnosis of idiopathic PAH. In fact,
in countries with an aging population, idiopathic PAH is reported to
be frequently diagnosed in elderly patients [11]. Elderly patients are
described to respond less well to medical therapy and have a higher
age-adjusted mortality compared with younger patients [11]. The
reason for this ﬁnding is unknown. Pulmonary hypertension, which
is ﬁrst considered as idiopathic, can be secondary to other hidden
causes, which were not diagnosed yet, similar to the clinical course
of the patient presented by Naito et al. The possibility of malignancy
should be considered in elderly patients manifesting pulmonary
hypertension because they are at the peak age of onset of malig-
nancy. Pulmonary tumor thrombotic microangiopathy related to
malignancy should also be considered as a differential diagnosis of
pulmonary hypertension [12].
The lesson learned from this case by Naito et al. is that an accu-
rate diagnosis is essential for treating patients with pulmonary
hypertension. Their patient did not respond to PAH-targeted drugs,
but to chemotherapy instead, which targeted IVL, possibly caus-
ing pulmonary hypertension. Naito et al. carefully followed up
their patient after initiation of PAH-targeted therapy, and this was
important for successful diagnosis and treatment. The diagnosis of
PAH always needs to be ensured because they are not approved
for treating pulmonary hypertension other than PAH. In particular,
vier Ltd. All rights reserved.
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pfront combination therapy is not yet proven to be better than
equential combination therapy in PAH [13]. To avoid delays in ﬁnal
iagnosis and adequate treatment, we should keep our eyes wide
pen for a sign that leads to a ﬁnal diagnosis, even after a tempo-
ary diagnosis of PAH is made and treatment is initiated. For those
atients who have an inadequate clinical response on follow-up,
he initial diagnosis should be reconsidered. If there are any unusual
ndings, necessary examinations should be performed to make an
ccurate diagnosis. Otherwise, treating patients with pulmonary
ypertension due to underlying disorders with PAH-targeted drugs
ould lead to an unfavorable clinical course of patients with high
ealthcare costs.
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